Posters

The three year comparative study of the development of posterior capsular opacification in two different types of hydrophobic acrylic one-piece IOLs

Poster Details

First Author: H.Kim SOUTH KOREA

Co Author(s):    S. Yoon                    

Abstract Details

Purpose:

To compare the long term development of posterior capsular opacification (PCO) and anterior capsular fibrosis (ACF) in two different types of hydrophobic acrylic intraocular lenses (IOL).

Setting:

Department of Ophthalmology, Catholic University of Daegu, Daegu, Korea.

Methods:

In this study, 180 eyes which had underwent cataract removal with phacoemulsification and in the bag implantation of either one of the two hydrophobic acrylic IOL (Acrysof IQ SN60WF & enVista MX60) by the same surgeon were evaluated more than 3 years. Cases with other visually disturbing conditions, previous intraocular surgery, or any complication during the surgery such as damaging lens capsule or zonule were excluded. Best corrected visual acuity(BCVA), uncorrected visual acuity(UCVA), the degree of PCO and anterior capsular fibrosis, and postoperative complications including glistenings of IOL optic were evaluated.

Results:

There were no significant differences of UCVA, BCVA, and the accuracy of postoperative refractive power between the two IOLs. At 12 months postoperatively, mild degree of PCO and ACF were developed in 4 out of 100 eyes with Acrysof IOLs and in 3 out of 80 eyes with enVista IOLs. At 3 years, moderate degree of PCO and ACF were developed in 16 eyes with Acrysof IOLs and in 14 eyes with enVista IOLs. At 3 years, moderate degree of glistenings appeared in 45 eyes with Acrysof IOLs. Mild degrees of glistening were developed in 2 eyes with enVista IOLs.

Conclusions:

The clinical outcomes and the development of PCO and ACF showed no differences between Acrysof and enVista IOLs throughout the 3 year follow up period. The moderate degrees of glistenings were developed in most of the AcrySof IOLs whereas only two enVista IOLs showed mild degree of glistenings.

Financial Disclosure:

NONE